Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (NasdaqGS:MRNA) from Buy to ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Key Takeaways The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price ...